These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 9704727

  • 1. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.
    Saliba F, Hagipantelli R, Misset JL, Bastian G, Vassal G, Bonnay M, Herait P, Cote C, Mahjoubi M, Mignard D, Cvitkovic E.
    J Clin Oncol; 1998 Aug; 16(8):2745-51. PubMed ID: 9704727
    [Abstract] [Full Text] [Related]

  • 2. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
    Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA, Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, Eckhardt SG, Weiss GR, Elfring GL, Rinaldi DA, Schaaf LJ, Von Hoff DD.
    J Clin Oncol; 1996 Apr; 14(4):1128-35. PubMed ID: 8648367
    [Abstract] [Full Text] [Related]

  • 3. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
    Freyer G, Rougier P, Bugat R, Droz JP, Marty M, Bleiberg H, Mignard D, Awad L, Herait P, Culine S, Trillet-Lenoir V.
    Br J Cancer; 2000 Aug; 83(4):431-7. PubMed ID: 10945486
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Phase II study of activated charcoal to prevent irinotecan-induced diarrhea.
    Michael M, Brittain M, Nagai J, Feld R, Hedley D, Oza A, Siu L, Moore MJ.
    J Clin Oncol; 2004 Nov 01; 22(21):4410-7. PubMed ID: 15514383
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy of prophylactic anti-diarrhoeal treatment in patients receiving Campto for advanced colorectal cancer.
    Duffour J, Gourgou S, Seitz JF, Senesse P, Boutet O, Castera D, Kramar A, Ychou M.
    Anticancer Res; 2002 Nov 01; 22(6B):3727-31. PubMed ID: 12552984
    [Abstract] [Full Text] [Related]

  • 9. [Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
    Couteau C, Yakendji K, Terret C, Goncalves E, Armand JP.
    Bull Cancer; 1996 Jan 01; 83(1):3-10. PubMed ID: 8672854
    [Abstract] [Full Text] [Related]

  • 10. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
    Pitot HC, Goldberg RM, Reid JM, Sloan JA, Skaff PA, Erlichman C, Rubin J, Burch PA, Adjei AA, Alberts SA, Schaaf LJ, Elfring G, Miller LL.
    Clin Cancer Res; 2000 Jun 01; 6(6):2236-44. PubMed ID: 10873073
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea.
    Abigerges D, Armand JP, Chabot GG, Da Costa L, Fadel E, Cote C, Hérait P, Gandia D.
    J Natl Cancer Inst; 1994 Mar 16; 86(6):446-9. PubMed ID: 8120919
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea.
    Pro B, Lozano R, Ajani JA.
    Invest New Drugs; 2001 Mar 16; 19(4):341-3. PubMed ID: 11561696
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
    Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P, Mahjoubi M.
    J Clin Oncol; 1997 Jan 16; 15(1):251-60. PubMed ID: 8996150
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective.
    Bleiberg H, Cvitkovic E.
    Eur J Cancer; 1996 Jan 16; 32A Suppl 3():S18-23. PubMed ID: 8943661
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea.
    Takasuna K, Hagiwara T, Watanabe K, Onose S, Yoshida S, Kumazawa E, Nagai E, Kamataki T.
    Cancer Chemother Pharmacol; 2006 Oct 16; 58(4):494-503. PubMed ID: 16437251
    [Abstract] [Full Text] [Related]

  • 20. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile.
    Rougier P, Bugat R.
    Semin Oncol; 1996 Feb 16; 23(1 Suppl 3):34-41. PubMed ID: 8633252
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.